Rivaroxaban (RXB) is a class II drug, according to the Biopharmaceutics Classification
System. Since its bioavailability is low at high doses, dose proportionality is not achieved for …

This study aims to improve the RXB bioavailability using hybrid nanoparticles. A modified
melt dispersion technique created different formulas with varying GMO-SAIB: RXB and GMO …

This study aimed to develop microspheres using water-soluble carriers and surfactants to
improve the solubility, dissolution, and oral bioavailability of rivaroxaban (RXB). RXB-loaded …

Background: Rivaroxaban is widely used for long-term prevention and maintenance therapy
of thromboembolic disorders. The existing oral dosage forms of rivaroxaban lead to poor …

This review article discusses Rivaroxaban (RXB), an anticoagulant that has gained much
attention due to its ability to prevent blood clots from forming in the body. However, one of …

The purpose of the currents study was to enhance bioavailability of rivaroxaban (RXB) and
reduce the food effect. RXB loaded PLGA nanoparticles (RXB-PLGA-NPs) were prepared by …

This study compares rivaroxaban-loaded polymeric microsphere systems with three types of
surface microstructure. Three types of polymeric microspheres loaded with rivaroxaban were …

This study aimed to investigate the use of Sucrose acetate isobutyrate (SAIB) and Glyceryl
monooleate (GMO) as co-formers for creating Cubosomes and SAIB-based nanodispersions …

The objective of the present study was to evaluate the potential of solid dispersion adsorbate
(SDA) to improve the solubility and bioavailability of rivaroxaban (RXN). SDA of RXN was …

Rivaroxaban (RXN) finds use in the management of pulmonary embolism and deep vein
thrombosis. Its poor solubility (5–7 µg/mL) and P-gp-mediated efflux from intestinal lining …